Protein Assays Market Size was valued at USD 1.22 Billion in 2023. The Protein Assays Market industry is projected to grow from USD 1.35 Billion in 2024 to USD 3.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.31% during the forecast period (2024 - 2032). Increasing developments across the healthcare industry and rising research & development activities are the prime market drivers expediting the market’s expansion.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Pixelgen Technologies, the single-cell spatial proteomics company, announced the commercial launch of its first kit in June 2023. The release was based on the company’s proprietary Molecular Pixelation (MPX) technology for immune cell surface proteins spatial analysis in 3D.
For example, as per an article published in February 2022 titled ‘Opto-Microfluidic Integration of the Bradford Protein Assay on Lithium Niobate Lab-on-a-Chip,’ a new protocol is presented here for protein quantification depending on the high correlation between light absorbance at 595 nm which is commonly used in Bradford method and that obtained at 633 nm using a cheap commercially available diode laser. The reason why this method offers more potential than others is that it allows reusing protein solutions and opto-microfluidic platforms for other studies thereby allowing them to grow the market of their protein assays.
For instance, Sengenics introduced the autoantibody profiling service Pan-Autoimmune Protein Array 1.0 – efficient identification and quantitation of autoantibody disease biomarker signatures – launched in March 2022. It is designed as a protein microarray-based multiplexed immunoassay with the use of Sengenics’ KREX protein folding technology and optimized computational analysis.
In March of the year, 2022 Biognosys unveiled an expanded set of proteomics platforms enabling deep biological insights for pharmaceutical and diagnostics customers across the entire R&D pipeline from early-stage discovery to clinical settings.
Amgen also partnered with Generate Biomedicines early last year to discover and develop protein therapeutics targeting five indications across multiple therapeutic areas and modalities, which required an initial investment worth $1.9 billion-plus.
For example, Canopy Biosciences launched assay kits for ChipCytometry in December 2021 together with Bruker Company. These Canopy assay kits will enable quantitative imaging of dozens of targeted protein biomarkers simultaneously within a single tissue section at single cell spatial resolution that will make it easier to use ChipCytometry for faster biological discovery. Hence, the drug discovery and development segment is expected to hold a significant share of the protein assay market because of all these reasons.
Market CAGR for protein assays is being driven by the rise in the spread of chronic diseases. During the study's forecast period, it is anticipated that the rapid rise in the prevalence of chronic diseases like cancer, cardiovascular disease, diabetes, and others, along with technological advancements and improvements in the protein assay technique, will have a significant positive impact on the market for protein assays. For instance, non-communicable diseases (NCDs) cause the deaths of about 41 million people annually, or 71 % of all deaths worldwide, according to a World Health Organization (WHO) update from April 2021. Additionally, more than 15 million people die from an NCD between the ages of 30 and 69, with 85 percent of these "premature" deaths taking place in low- and middle-income countries.
Additionally, 19.3 million new cases of cancer were diagnosed ly in 2020, and the International Agency for Research on Cancer (Globocan 2020) predicts that this figure would rise to 28.9 million new cases by the year 2040. Thus, the demand for protein assays is anticipated to rapidly expand for various applications such as drug discovery and development, illness screening and diagnosis, and others, which would promote market expansion due to the rising spread of chronic diseases and mortality from them.
The market for protein assays is also anticipated to rise as a result of the research being done in the field and technological developments in the protein assay field. For instance, according to a February 2022 article titled "Opto-Microfluidic Integration of the Bradford Protein Assay in Lithium Niobate Lab-on-a-Chip", a new protocol is proposed to carry out protein quantification based on the strong correlation between the light absorbance at 595 nm, as is frequently used in the Bradford method, and the one achieved at 633 nm with a reasonably priced commercially available diode laser. This approach shows that it is possible to quantify proteins using nL quantities, which are 1000 times smaller than those required by conventional methods like paper-analytical instruments. Thus, driving the Protein Assays Market revenue.
The Protein Assays Market segmentation, based on type includes Copper-ion-based assays, Test-strip-based assays, and Dye-Binding assays. It is projected that the dye-binding assays segment's market share would grow steadily. The capacity of this kind of test to diagnose a wide range of chronic disorders, such as Alzheimer's and cancer, is one of its main advantages.
The Protein Assays Market segmentation, based on product, includes Reagents & kits, Instruments. According to the product, the Reagents & kits market for protein assays is predicted to grow at a significant CAGR. The product's capacity to enable quick and ready-to-use modifications and the rising number of repeat purchases of reagents can be credited to the segmental expansion.
The Protein Assays Market segmentation, based on application, includes Diagnosis, Drug discovery, and Protein purification. The value of the worldwide protein assay market from the drug discovery category will significantly rise based on application. The various applications of protein assays at various stages of pre-clinical & clinical trials, as well as the final stages of the drug development process, can be credited with the segmental expansion.
The Protein Assays Market segmentation, based on technology, includes Colorimetric-Based Protein Assays, Fluorescence-based protein assays, and Absorbance-based protein assays. The market segment predicted to hold the biggest proportion is absorbance-based protein tests. The development of novel methodologies has led to an increase in the sensitivity and accuracy of absorbance-based protein tests, which is largely responsible for this market's expansion.
The Protein Assays Market segmentation, based on end-user, includes Hospitals & Diagnostics Centers, Academic Institutes, Pharmaceutical & Biotechnology Companies, and Others. Over the next few years, this sector will present significant growth prospects for pharmaceutical & biotechnology companies. Numerous developments in the life sciences industry's drug development process could hasten the use of protein assays even more.
Figure 1 Protein Assays Market, by End-User, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and, the Rest of the World. The North America Protein Assays Market area will dominate this market. Due to the region's high prevalence of chronic diseases, extensive healthcare infrastructure, and the presence of a large pharmaceutical market and significant investments in drug development and discovery initiatives by some of the largest pharmaceutical companies that are based there.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 PROTEIN ASSAYS MARKET SHARE BY REGION 2023 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Protein Assays Market accounts for the second-largest position in the market. Market expansion will be fueled by the region's substantial investment in a variety of publicly and privately financed research and development activities as well as the region's steadily expanding spending on the improvement of the pharmaceutical and biotechnology industries. Further, the German Protein Assays Market held the largest market share, and the UK Protein Assays Market was the quickest-growing market in the European region
The Asia Pacific Protein Assays Market is anticipated to expand at the quickest CAGR from 2023 to 2032. This is due to the industry's increased emphasis on research and development as well as the speedy expansion of the healthcare infrastructure. Moreover, China Protein Assays Market held the fastest CAGR, and the India Protein Assays Market was the quickest-growing market in the Asia-Pacific region.
Protein Assays Key Market Players & Competitive Insights
Leading market players are investing largely in research and development to grow their product/service lines, which will aid the Protein Assays Market, to grow even faster. Market leaders are also adopting a variety of strategies to expand their worldwide position, with important market developments including new product launches & developments, contractual agreements among companies with complementary service lines, mergers & acquisitions, higher investments, & collaboration with other organizations having complementary products and services. To expand and survive in a more competitive and rising market climate, the Protein Assays industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Protein Assays industry to benefit clients and increase the market sector. In recent years, the Protein Assays industry has offered some of the most significant advantages to medicine. Major players in the Protein Assays Market, including GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology Inc. (U.S), Abcam plc (U.S.), Lucigen Corporation (U.S.), PerkinElmer Inc. (U.S.), and QIAGEN (Germany), and others are attempting to increase market growth via investing in research and development operations.
Abcam Plc (Abcam) is a provider of life science research instruments for the molecular analysis of living cells to comprehend a variety of illness situations. The business creates and sells antibodies as well as associated goods. Primary antibodies, secondary antibodies, immunoassay kits, and reagents, tools for imaging cells and tissues, cellular and biochemical assays, proteomics tools, proteins and peptides, activators, agonists, antagonists, inhibitors, lysates, multiplex miRNA assay are all included in its product line. The products made by Abcam help researchers in the biological sciences and veterinary sciences find proteins. In November 2021, Abcam, a leading innovator in life sciences research tools, and Nautilus Biotechnology, Inc., a business developing a single-molecule protein analysis platform for characterizing the proteome, recently established a strategic supply and development relationship.
Cell Signaling Technology (CST), a private, family-owned business founded in 1999 by research scientists, takes pride in operating as a research institute and creating high-quality goods for other researchers. CST is engaged in practical systems biology research and is aware of the value of utilizing antibodies, particularly in the context of cancer research. Diagnostic research services are offered by Cell Signalling Technology, Inc. The business provides research in biological chemistry, cell, the Journal of Immunology, and natural biotechnology. Cell Signalling Technology is available everywhere. In February 2023, Cell Signalling Technology (CST) and Bio-Techne Corporation announced the addition of Simple Western validation to CST antibodies. This will make it simpler for academics across disciplines to examine crucial molecular signaling pathways on a reliable and established platform.
Key Companies in the Protein Assays Market include
Protein Assays Industry Developments
March 2022 To give its customers in the pharmaceutical and diagnostics industries rich biological insights across the whole R&D pipeline, from early-stage discovery to clinical settings, Biognosys recently announced an extended range of proteomics systems.
January 2022 Amgen and Generate Biomedicines collaborated to find and develop protein therapies for five targets, spanning numerous therapeutic modalities and therapeutic regions, with an initial investment of more than USD 1.9 billion.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)